

## ORIGINAL ARTICLE

# Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

C.U. Blank, M.W. Lucas, R.A. Scolyer, B.A. van de Wiel, A.M. Menzies, M. Lopez-Yurda, L.L. Hoeijmakers, R.P.M. Saw, J.M. Lijnsvelt, N.G. Maher, S.M. Pulleman, M. Gonzalez, A. Torres Acosta, W.J. van Houdt, S.N. Lo, A.M.J. Kuijpers, A. Spillane, W.M.C. Klop, T.E. Pennington, C.L. Zuur, K.F. Shannon, B.A. Seinstra, R.V. Rawson, J.B.A.G. Haanen, S. Ch'ng, K.A.T. Naipal, J. Stretch, J.V. van Thienen, M.A. Rtshiladze, S. Wilgenhof, R. Kapoor, A. Meerveld-Eggink, L.G. Grijpink-Ongering, A.C.J. van Akkooi, I.L.M. Reijers, D.E. Gyorki, D.J. Grünhagen, F.M. Speetjens, S.B. Vlieg, J. Placzke, L. Spain, R.C. Stassen, M. Amini-Adle, C. Lebbé, M.B. Faries, C. Robert, P.A. Ascierto, R. van Rijn, F.W.P.J. van den Bergmotel, D. Piersma, A. van der Westhuizen, G. Vreugdenhil, M.J.B. Aarts, M.A.M. Stevense-den Boer, V. Atkinson, M. Khattak, M.C. Andrews, A.J.M. van den Eertwegh, M.J. Boers-Sonderen, G.A.P. Hospers, M.S. Carlino, J.-W.B. de Groot, E. Kapiteijn, K.P.M. Suijkerbuijk, P. Rutkowski, S. Sandhu, A.A.M. van der Veldt, and G.V. Long

## ABSTRACT

**BACKGROUND**

In phase 1–2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy.

**METHODS**

In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. Only patients in the neoadjuvant group with a partial response or nonresponse received adjuvant treatment. The primary end point was event-free survival.

**RESULTS**

A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05;  $P < 0.001$ ; hazard ratio for progression, recurrence, or death, 0.32; 99.9% CI, 0.15 to 0.66). In the neoadjuvant group, 59.0% of patients had a major pathological response, 8.0% had a partial response, 26.4% had a nonresponse ( $>50\%$  residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% in patients in the neoadjuvant group who had a major pathological response, 76.1% among those with a partial response, and 57.0% among those with a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of patients in the neoadjuvant group and in 14.7% in the adjuvant group.

**CONCLUSIONS**

Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Dr. Blank can be contacted at [c.blank@nki.nl](mailto:c.blank@nki.nl) or at the Netherlands Cancer Institute, Department of Medical Oncology and Division of Molecular Oncology and Immunology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Drs. Blank and Lucas contributed equally to this article.

This article was published on June 2, 2024, and updated on June 6, 2024, at [NEJM.org](https://www.nejm.org).

N Engl J Med 2024;391:1696-708.

DOI: 10.1056/NEJMoa2402604

Copyright © 2024 Massachusetts Medical Society.

THE STANDARD MANAGEMENT OF REsectable, macroscopic stage III melanoma is currently surgery, which can be followed by adjuvant systemic therapy. The programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab both have been shown to prolong recurrence-free survival as compared with either the cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab (52% with nivolumab and 41% with ipilimumab at 4 years) or placebo (55% with pembrolizumab and 38% with placebo at 5 years).<sup>1,2</sup> Among patients with melanoma with a BRAF V600E or V600K mutation, BRAF-targeted therapy with dabrafenib plus trametinib has shown a benefit as compared with placebo (recurrence-free survival, 54% with dabrafenib plus trametinib and 38% with placebo at 4 years).<sup>3</sup> Despite adjuvant systemic treatment, a substantial proportion of patients have disease recurrence within the first few years after surgery. In addition, none of the approved adjuvant immunotherapies have shown a significant overall survival benefit despite long-term follow-up,<sup>2,4</sup> a finding that emphasizes the need for new treatment approaches.

On the basis of preclinical and phase 1 data, neoadjuvant administration of immune checkpoint inhibitors is hypothesized to yield efficacy superior to that of adjuvant administration.<sup>5,6</sup> A recent randomized phase 2 trial (the Southwest Oncology Group Cancer Research Network S1801 trial [SWOG S1801]) showed that event-free survival was longer among patients who received three neoadjuvant cycles of pembrolizumab every 3 weeks (followed by 15 adjuvant cycles) than among patients who received 18 adjuvant cycles of pembrolizumab (estimated 2-year event-free survival, 72% vs. 49%; hazard ratio, 0.58;  $P=0.004$ ).<sup>7,8</sup> Another phase 2 trial showed, in two independent cohorts, that a neoadjuvant combination regimen of two cycles of ipilimumab (at a dose of 1 mg per kilogram of body weight) plus nivolumab (at a dose of 3 mg per kilogram every 3 weeks) resulted in an event-free survival of 77 to 80% at 2 years, a finding that suggests an even higher efficacy than neoadjuvant anti-PD-1 monotherapy. Furthermore, this combination regimen was deemed to be safe, with grade 3 or 4 adverse events occurring in 27 to 30% of the patients and surgery being omitted in only 1% of the patients because of toxic effects.<sup>9-11</sup> Collectively, these data provided the rationale for test-

ing this neoadjuvant regimen against the current standard care of adjuvant anti-PD-1 in the randomized phase 3 NADINA (Neoadjuvant Ipilimumab plus Nivolumab versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma) trial.

## METHODS

### PATIENTS

We enrolled patients who were at least 16 years of age and had resectable, macroscopic stage III cutaneous or acral melanoma or melanoma of unknown primary origin (according to the eighth edition of the *Cancer Staging Manual* of the American Joint Committee on Cancer) with at least one pathologically proven lymph-node metastasis and a maximum of three additional in-transit metastases. Patients with concurrent primary melanoma were eligible for inclusion. Macroscopic disease was defined as a pathologically proven lymph-node metastasis that was palpable, positive according to positron-emission tomography, or measurable on imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.<sup>12</sup> Complete eligibility criteria are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.

### TRIAL DESIGN AND TREATMENT

In this multicenter, international, phase 3 trial, patients were randomly assigned in a 1:1 ratio to receive either neoadjuvant or adjuvant immune checkpoint inhibition. Patients in the neoadjuvant group received two cycles of neoadjuvant ipilimumab (at a dose of 80 mg) plus nivolumab (at a dose of 240 mg) every 3 weeks,<sup>9,11</sup> followed by a therapeutic lymph-node dissection and, if applicable, resection of the in-transit metastases in week 6. Patients who had a locally assessed major pathological response ( $\leq 10\%$  residual viable tumor) did not receive any adjuvant treatment, and patients who had a pathological partial response (11 to 50% residual viable tumor) or a pathological nonresponse ( $>50\%$  residual viable tumor) received adjuvant dabrafenib (at a dose of 150 mg twice daily) plus trametinib (at a dose of 2 mg once daily) for 46 weeks if the melanoma had a BRAF V600E or V600K mutation or received an additional 11 cycles of adjuvant nivolumab (at a dose of 480 mg) every 4 weeks if the melanoma was BRAF wild type. Patients in



A Quick Take  
is available at  
NEJM.org



the adjuvant group underwent a therapeutic lymph-node dissection in week 0 followed by 12 cycles of adjuvant nivolumab every 4 weeks starting between week 6 and 12. Adjuvant radiotherapy was allowed in both groups, with the exception of patients who had a major pathological response after neoadjuvant treatment. Stratification factors included continent, the presence of a BRAF V600E or V600K mutation, and the presence of in-transit metastases (Fig. S1 in the Supplementary Appendix).

Treatment was discontinued if progression, death, unacceptable toxic effects, or withdrawal of consent occurred. Dose reductions of ipilimumab and nivolumab were not allowed. Additional details regarding dose delays, dose reductions of dabrafenib and trametinib, and the management of adverse events are provided in the protocol, available at NEJM.org.

#### END POINTS AND ASSESSMENTS

The primary end point was event-free survival, which was defined as the time from randomization to the occurrence of progression to unresectable melanoma before surgery, disease recurrence, or death due to melanoma or due to treatment. Data for patients who did not have an event were censored on the date of the last reported imaging. The key secondary end point was overall survival, and additional secondary end points included recurrence-free survival, distant metastasis-free survival, pathological response, safety measures, and measures of health-related quality of life. The assessment of pathological response was conducted according to the International Neoadjuvant Melanoma Consortium criteria, and retrospective central review was performed at the Netherlands Cancer Institute or the Melanoma Institute Australia.<sup>13</sup> Details regarding radiologic and pathological assessments are provided in the Supplementary Appendix. Adverse events were scored with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

#### TRIAL OVERSIGHT

The Netherlands Cancer Institute was responsible for oversight of the trial, and Melanoma Institute Australia was responsible for oversight of the participating centers in Australia. The protocol was written by investigators from both institutes and was approved by independent ethics committees or institutional review boards of the

coordinating center of each participating country. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All the enrolled patients provided written informed consent. Data were collected and analyzed by the Netherlands Cancer Institute and Melanoma Institute Australia. The first two authors and the last author developed the first draft of the manuscript, and all coauthors contributed to the final version submitted for publication. No external writers were involved. The authors vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol. An independent data and safety monitoring board was appointed to monitor the progress of the trial. On February 20, 2024, the data and safety monitoring board advised the investigators about the results of the first interim analysis and recommended that the results be reported. Data on overall survival remain blinded until the prespecified final analysis at 3 years after the last patient is enrolled.

#### STATISTICAL ANALYSIS

We planned to enroll 420 patients. It was estimated that 132 events would provide the trial with 90.5% power to show superiority of neoadjuvant treatment over adjuvant treatment, under the assumption of a 24-month event-free survival of 75% in the neoadjuvant group and 60% in the adjuvant group, with the use of a log-rank test with a two-sided alpha level of 5% for the final analysis. The prespecified interim analysis was conducted with the use of a two-sided alpha level of 0.1%, which conforms to the Haybittle-Peto stopping rule. Given the positive results, the first interim analysis became the final analysis for event-free survival. Details regarding a statistical amendment to the protocol are provided in the Supplementary Appendix.

The primary end point, event-free survival, was assessed in the intention-to-treat population, which included all the patients who had undergone randomization. Hazard ratios and corresponding 99.9% confidence intervals were estimated with the use of a multivariable Cox proportional-hazards model, with adjustment for the randomization stratification factors. The Kolmogorov-type supremum test was used to assess deviations from the proportional-hazards assumption.<sup>14</sup> For analyses in which this assumption was violated, we estimated the differ-

ence in restricted mean survival time between the treatment groups with adjustment for the stratification factors at randomization. The restriction time was determined on the basis of the shortest maximum follow-up in the two treatment groups. Event-free survival curves were estimated with the use of the Kaplan–Meier method, and 12-month event-free survival and 99.9% confidence intervals were calculated. Safety data were summarized for all the patients who started treatment; adverse events related to systemic treatment were assessed in all the patients who received at least one cycle of systemic treatment, and adverse events related to surgery were assessed in all the patients who underwent surgery. Pathological response was assessed in all the patients who were enrolled in the neoadjuvant group who received at least one cycle of neoadjuvant therapy.

The statistical analysis plan did not include a provision for correcting for multiplicity when conducting tests for secondary end points or in subgroups, so the widths of the confidence intervals have not been adjusted for multiplicity and should not be used to infer definitive treatment effects. All statistical analyses were performed with the use of SAS software, version 9.4 (SAS Institute), and R software, version 4.2.1 (R Foundation for Statistical Computing).

## RESULTS

### PATIENTS AND TREATMENT

From July 2021 through December 2023, a total of 423 patients underwent randomization; 212 were assigned to the neoadjuvant group and 211 were assigned to the adjuvant group. The characteristics of the patients at baseline were balanced between the groups, and the trial population was considered to be representative of the overall population with stage III melanoma (Table 1 and Table S2). Three patients in the adjuvant group did not undergo surgery and thus did not start treatment according to the protocol (Fig. S2). In the neoadjuvant group, all the patients started systemic therapy; 199 of 212 patients (93.9%) received the prespecified two cycles of neoadjuvant ipilimumab plus nivolumab. Surgery was performed in 198 patients (93.4%) in the neoadjuvant group; these procedures were performed on time (within 1 week before or after the protocol-specified timing) in 162 patients

(81.8%). The median time from the start of neoadjuvant treatment to surgery was 45.0 days (interquartile range, 42.0 to 49.0). A total of 197 patients underwent a therapeutic lymph-node dissection, and 1 patient had an index lymph-node procedure.<sup>11</sup> Surgery was not performed in patients in the neoadjuvant group because of toxic effects (in 3 patients), progression (in 5 patients), and an unknown reason (in 1 patient). Surgery was planned for after the data-cutoff date in 5 patients. In the adjuvant group, 207 therapeutic lymph-node dissections were performed, and 1 selective lymph-node dissection was performed. Of these procedures, 205 (98.6%) were performed on time. The median number of resected lymph nodes per region was 18 (interquartile range, 13 to 27) in the neoadjuvant group and 17 (interquartile range, 11 to 25) in the adjuvant group (Table S3). Of the 78 patients in the neoadjuvant group who were intended to receive adjuvant therapy because of the lack of major pathological response, 65 (83.3%) started systemic adjuvant treatment. In the adjuvant group, 170 of 208 patients (81.7%) started treatment with nivolumab (Fig. S3 and Table S4).

### EFFICACY

#### *Results in the Intention-to-Treat Population*

At the time of data cutoff (January 12, 2024), the median duration of follow-up was 10.6 months (interquartile range, 5.2 to 16.8) in the neoadjuvant group and 9.9 months (interquartile range, 4.6 to 16.8) in the adjuvant group. A total of 100 events (progression, recurrence, or death from melanoma or treatment) had occurred in the intention-to-treat population, of which 28 were in the neoadjuvant group and 72 in the adjuvant group. Event-free survival was significantly longer in the neoadjuvant group than in the adjuvant group; the estimated event-free survival at 12 months was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) and 57.2% (99.9% CI, 45.1 to 72.7), respectively (Fig. 1 and Table S5).

The Kolmogorov-type supremum test indicated a violation of the proportional-hazards assumption ( $P=0.04$ ), which was attributed to the wider separation of the curves in the first months after randomization. The adjusted difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05;  $P<0.001$ ), at a restriction time of 27.8 months. The results of sensitivity analyses incorporating piecewise hazard functions to address nonproportionality showed con-

**Table 1. Characteristics of the Patients at Baseline.\***

Characteristic	Neoadjuvant Group (N=212)	Adjuvant Group (N=211)
Sex — no. (%)		
Female	71 (33.5)	76 (36.0)
Male	141 (66.5)	135 (64.0)
Median age (range) — yr	60 (22–84)	59 (19–87)
Continent — no. (%)		
Australia	71 (33.5)	71 (33.6)
Europe	141 (66.5)	139 (65.9)
North America	0	1 (0.5)
Median weight (range) — kg†	85.1 (52.0–144.0)	83.1 (49.0–151.0)
Median body-mass index (range)†	27.6 (19.1–52.3)	26.9 (19.1–42.0)
WHO performance-status score — no. (%)‡		
0	192 (90.6)	192 (91.0)
1	20 (9.4)	19 (9.0)
Tumor stage — no. (%)§		
T1	25 (11.8)	36 (17.1)
T2	41 (19.3)	39 (18.5)
T3	41 (19.3)	49 (23.2)
T4	52 (24.5)	46 (21.8)
Tx	7 (3.3)	6 (2.8)
Melanoma of unknown primary origin	46 (21.7)	35 (16.6)
Ulceration — no. (%)		
Yes	71 (33.5)	57 (27.0)
No	85 (40.1)	102 (48.3)
Melanoma of unknown primary origin	46 (21.7)	35 (16.6)
Unknown	10 (4.7)	17 (8.1)
In-transit metastases — no. (%)		
Yes	22 (10.4)	25 (11.8)
No	190 (89.6)	186 (88.2)
Short-axis diameter of largest lymph node — no. (%)¶		
<15 mm	67 (31.6)	74 (35.1)
15–30 mm	115 (54.2)	102 (48.3)
31–50 mm	24 (11.3)	29 (13.7)
>50 mm	4 (1.9)	4 (1.9)
No lymph node reported on CT scan	2 (0.9)	2 (0.9)
Median sum of diameters of lymph nodes (range) — mm²	25 (15–74)	25 (15–82)
Location or locations of affected lymph nodes — no./total no. (%)		
Neck	55/211 (26.1)	57/211 (27.0)
Axilla	86/211 (40.8)	86/211 (40.8)
Groin	66/211 (31.3)	66/211 (31.3)



**Table 1. (Continued.)**

Characteristic	Neoadjuvant Group (N=212)	Adjuvant Group (N=211)
Axilla and neck	3/211 (1.4)	0
Other	1/211 (0.5)	2/211 (0.9)
No. of lymph nodes positive for disease on PET — no./total no. (%)**		
1	126/200 (63.0)	122/205 (59.5)
2 or 3	52/200 (26.0)	64/205 (31.2)
>3	17/200 (8.5)	12/205 (5.9)
0	5/200 (2.5)	7/205 (3.4)
<i>BRAF</i> mutation status — no. (%)		
V600E	95 (44.8)	87 (41.2)
V600K	17 (8.0)	25 (11.8)
Other <i>BRAF</i> mutation	5 (2.4)	4 (1.9)
Wild type	95 (44.8)	95 (45.0)
LDH level — no. (%)		
<ULN	196 (92.5)	192 (91.0)
1–1.5×ULN	16 (7.5)	19 (9.0)
Previous surgical treatment to nodal basin — no. (%)		
Sentinel-node procedure	75 (35.4)	78 (37.0)
Lymph-node dissection	1 (0.5)	1 (0.5)
Both procedures	0	3 (1.4)
None	136 (64.2)	129 (61.1)

\* Data shown are for the intention-to-treat population, which included all the patients who had undergone randomization. Percentages may not total 100 because of rounding. LDH denotes lactate dehydrogenase, PET positron-emission tomography, and ULN upper limit of the normal range.

† The weight and body-mass index (the weight in kilograms divided by the square of the height in meters) are missing for 1 patient in the neoadjuvant group and 5 patients in the adjuvant group.

‡ World Health Organization (WHO) performance-status scores range from 0 to 5, with higher numbers indicating greater disability.

§ The stages are defined according to the eighth edition of the *Cancer Staging Manual* of the American Joint Committee on Cancer.

¶ The sums of the diameters of the lymph nodes that were longer than 15 mm at the shortest axis were measured on the baseline computed tomographic (CT) scan, in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Data were missing for 68 patients in the neoadjuvant group and 76 patients in the adjuvant group.

|| The locations of lymph nodes are based on the baseline CT scan. Data were missing for 3 patients in the neoadjuvant group and 5 patients in the adjuvant group and were thus determined on the basis of surgical information for 2 patients in the neoadjuvant group and 5 patients in the adjuvant group.

\*\* Patients were eligible for inclusion in the trial if they had a pathologically proven lymph node that could be assessed with the use of RECIST, was positive for disease according to PET, or was palpable at baseline.

sistency with an overall adjusted hazard ratio of 0.32 (99.9% CI, 0.15 to 0.66). One death that was not related to melanoma or treatment (as determined by the local investigator) occurred before the occurrence of progression or disease recurrence. A sensitivity analysis accounting for competing risks yielded similar results to those of the primary analysis. The results of subgroup analyses that were performed according to base-

line characteristics were consistent with those in the intention-to-treat population (Fig. S6).

#### *Response in the Overall Neoadjuvant Group*

In the neoadjuvant group, all 212 patients received at least one dose of neoadjuvant immunotherapy and could therefore be assessed for pathological response. As determined by central review, 47.2% of the patients had a pathological

**Table 2. Pathological Responses in the Neoadjuvant Group.\***

Type of Response	Local Assessment (N=212)	Central Review (N=212)
	number (percent)	
Major pathological response	120 (56.6)	125 (59.0)
Pathological complete response†	97 (45.8)	100 (47.2)
Pathological near-complete response	23 (10.8)	25 (11.8)
Pathological partial response	20 (9.4)	17 (8.0)
Pathological nonresponse	53 (25.0)	56 (26.4)
Progression before surgery	5 (2.4)	5 (2.4)
Not reported	5 (2.4)	0
Not available‡	9 (4.2)	9 (4.2)

\* Patients in the neoadjuvant group who received at least one dose of neoadjuvant treatment were assessed for pathological response. The pathological response was determined according to the International Neoadjuvant Melanoma Consortium criteria. A pathological complete response was defined as 0% residual viable tumor in the surgical resection specimen, pathological near-complete response as 0 to 10% residual viable tumor, pathological partial response as 11 to 50% residual viable tumor, and pathological nonresponse as more than 50% residual viable tumor. Major pathological response included pathological complete response and pathological near-complete response.

† As confirmed by central review, the material from surgical resection in 9 of 100 patients who had a complete pathological response did not show any signs of viable or regressed tumor, nor were there clinical indications that the tumor was still in situ.

‡ At the time of the data cutoff, no material from surgical resection was available for 9 patients (5 patients underwent surgery after the data-cutoff date, 3 patients had not undergone surgery because of toxic effects, and 1 patient had not undergone surgery for an unknown reason).

complete response (0% residual viable tumor) and 11.8% had a pathological near-complete response (1 to 10% residual viable tumor), which yielded a major pathological response of 59.0%. Furthermore, 8.0% of the patients had a pathological partial response, 26.4% had a pathological nonresponse, and 2.4% had progression before surgery; in 4.2%, surgery had not yet been performed or was omitted (Table 2 and Fig. S7). Discordances between local and central assessment of pathological responses were infrequent and predominantly underestimated the depth of response; only 1 of 120 patients (0.8%) were classified as not having had a major pathological response according to central review instead of having had a major pathological response, and 4 of 74 patients (5.4%) were classified as having had a major pathological response instead of no major pathological response. Objective radiologic responses at week 6 occurred in 76 patients (35.8%) (Table S6).


#### *Efficacy According to BRAF Mutation Status*

The estimated event-free survival at 12 months among patients with melanoma with a BRAF

V600E or V600K mutation was 83.5% (99.9% CI, 70.3 to 99.2) in the neoadjuvant group and 52.2% (99.9% CI, 35.9 to 75.8) in the adjuvant group (unadjusted hazard ratio for progression, recurrence, or death, 0.29; 99.9% CI, 0.11 to 0.79). Among patients with BRAF wild-type melanoma, the estimated event-free survival at 12 months was 83.9% (99.9% CI, 70.1 to 99.9) in the neoadjuvant group and 62.4% (99.9% CI, 46.0 to 84.7) in the adjuvant group (unadjusted hazard ratio for progression, recurrence, or death, 0.35; 99.9% CI, 0.12 to 1.03) (Fig. 2A and 2B). Among patients in the neoadjuvant group, 53.8% of those with BRAF-mutated melanoma and 65.3% of those with BRAF wild-type melanoma had a major pathological response.

#### *Efficacy According to Pathological Response*

Among the 212 patients in the neoadjuvant group, 198 patients (93.4%) had a major pathological response, a pathological partial response, or a pathological nonresponse and could be assessed for recurrence-free survival; the analysis was subdivided according to response category. The estimated recurrence-free survival at 12 months was



95.1% (99.9% CI, 87.4 to 99.9) among patients who had a major pathological response, 76.1% (99.9% CI, 44.4 to 99.9) among those who had a pathological partial response, and 57.0% (99.9% CI, 33.3 to 97.6) among those who had a pathological nonresponse (Fig. 2C). Among the patients who had a pathological complete response, the estimated recurrence-free survival was 95.4% (99.9% CI, 87.0 to 99.9); among those who had a pathological near-complete response, the estimated recurrence-free survival was 94.1% (99.9% CI, 77.1 to 99.9) (Fig. S8).

#### SAFETY


Adverse events of any cause of grade 3 or higher were reported in 47.2% of the patients in the neoadjuvant group and in 34.1% in the adjuvant group. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of the patients in the neoadjuvant group and in 14.7% of the patients in the adjuvant group, and surgery-related adverse events of grade 3 or higher occurred in 14.1% and 14.4% of the patients, respectively. In the neoadjuvant group, 23.1% of the patients had an adverse event of grade 3 or higher that was related to systemic treatment within the first 12 weeks and was therefore attributable solely to the neoadju-

vant treatment. Endocrinopathies related to systemic treatment occurred in 30.7% of the patients in the neoadjuvant group and in 9.9% of those in the adjuvant group. At the time of the data cutoff, the events were ongoing in 25.0% of the patients in the neoadjuvant group and in 7.5% of the patients in the adjuvant group; the most frequent events were hypothyroidism (in 11.3% and 6.5%, respectively) and adrenal insufficiency (in 7.1% and 1.2%, respectively) (Table S10). No new adverse events related to nivolumab with or without ipilimumab or related to dabrafenib plus trametinib occurred. Serious adverse events were reported in 36.3% of the patients in the neoadjuvant group and in 24.0% of those in the adjuvant group. In the adjuvant group, one patient died from pneumonitis caused by nivolumab. In the neoadjuvant group, no treatment-related deaths occurred (Table 3 and Tables S7 through S11).


#### DISCUSSION

NADINA, a phase 3, investigator-initiated trial comparing neoadjuvant with adjuvant immunotherapy in resectable, macroscopic stage III melanoma, is distinctive in that it is evaluating a neoadjuvant regimen of immunotherapy alone.




**A Event-free Survival among Patients with Melanoma with *BRAF* V600E or V600K Mutation****No. at Risk (no. censored)**

Neoadjuvant	112 (0)	63 (40)	38 (61)	18 (81)	3 (94)
Adjuvant	112 (0)	48 (32)	25 (47)	11 (60)	4 (67)

**B Event-free Survival among Patients with *BRAF* Wild-Type Melanoma****No. at Risk (no. censored)**

Neoadjuvant	100 (0)	63 (31)	39 (50)	16 (71)	2 (85)
Adjuvant	99 (0)	52 (25)	28 (42)	12 (56)	2 (66)

**C Recurrence-free Survival According to Pathological Response****No. at Risk (no. censored)**

Major pathological response	125 (0)	76 (46)	55 (66)	22 (99)	2 (118)
Pathological partial response	17 (0)	11 (5)	5 (9)	2 (12)	
Pathological nonresponse	56 (0)	29 (17)	11 (30)	1 (39)	

**Figure 2 (facing page). Event-free Survival According to BRAF Mutation Status and Recurrence-free Survival.**

Panel A shows the Kaplan–Meier curves for event-free survival among patients with melanoma with *BRAF* V600E or V600K mutation. The event-free survival at 12 months was 83.5% (99.9% CI, 70.3 to 99.2) in the neoadjuvant group and 52.2% (99.9% CI, 35.9 to 75.8) in the adjuvant group. Panel B shows the Kaplan–Meier curves for event-free survival among patients with *BRAF* wild-type melanoma. The event-free survival at 12 months was 83.9% (99.9% CI, 70.1 to 99.9) in the neoadjuvant group and 62.4% (99.9% CI, 46.0 to 84.7) in the adjuvant group. Panel C shows the Kaplan–Meier curves for recurrence-free survival according to pathological response category among patients in the neoadjuvant group. At 12 months, the recurrence-free survival was 95.1% (99.9% CI, 87.4 to 99.9) among patients who had a major pathological response ( $\leq 10\%$  residual viable tumor), 76.1% (99.9% CI, 44.4 to 99.9) among patients who had a pathological partial response (11 to 50% residual viable tumor), and 57.0% (99.9% CI, 33.3 to 97.6) among patients who had a pathological nonresponse ( $>50\%$  residual viable tumor). The widths of the confidence intervals have not been adjusted for multiplicity and should not be used to infer definitive treatment effects. The tick marks in all panels indicate censored data.

Here, we show that two cycles of ipilimumab plus nivolumab followed by a therapeutic lymph-node dissection and response-driven adjuvant treatment resulted in longer event-free survival than adjuvant treatment, with an absolute reduction of 27 percentage points in the risk of an event in the first 12 months as compared with the current standard care of up-front therapeutic lymph-node dissection followed by 12 cycles of adjuvant nivolumab.

The results in the neoadjuvant group (an estimated event-free survival at 12 months of 83.7% and a major pathological response in 59.0% of the patients) are in line with the efficacy found in the preceding phase 2 trials that evaluated neoadjuvant ipilimumab plus nivolumab (the Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab [OpACIN-neo] trial and the Personalized Response-Driven Adjuvant Therapy after OpACIN [PRADO] trial), in which the event-free survival at 12 months was 85 to 86%, and 60 to 61% of the patients had a major pathological response.<sup>9–11</sup> Updated data from the OpACIN-neo trial indicate that these outcomes are durable (recurrence-free survival at 3 years, 82%) and translate into a remarkable overall survival of 92% at 3 years.<sup>15</sup> The estimated event-free sur-

vival at 12 months in the adjuvant group (57.2%) in the current trial is lower than the recurrence-free survival at 12 months observed in the CheckMate 238 trial and the European Organization for Research and Treatment of Cancer (EORTC) 1325 trial (70.5% and 75.4% in the two trials, respectively), both of which evaluated adjuvant anti-PD-1 monotherapy.<sup>16,17</sup> This difference is most likely due to the inclusion of lower-risk patients with microscopic stage III melanoma, as well as the exclusion of patients with early recurrence before the start of adjuvant therapy, in the other two trials. Early disease recurrence before the start of adjuvant therapy is reflected in the reported 10 to 20% of patients in these trials who were excluded at screening because of recurrence, as well as in observations from the SWOG S1801 trial and retrospective reports.<sup>7,18,19</sup>

In this trial, we found a similar event-free survival in the neoadjuvant group regardless of *BRAF* mutational status. However, in the adjuvant group, event-free survival was shorter among the patients with *BRAF*-mutated melanoma than among those with *BRAF* wild-type melanoma. This finding indicates a benefit from the addition of ipilimumab, as previously observed for stage IV melanoma,<sup>20</sup> and potentially from the class switch for the patients with *BRAF*-mutated melanoma who had a partial response or no response. On the basis of the difference in major pathological response (53.8% of the patients with *BRAF*-mutated melanoma and 65.3% of the patients with *BRAF* wild-type melanoma) and the similarity in event-free survival, we estimate that this class switch may have accounted for an increase in 12-month event-free survival in the neoadjuvant group of approximately 5 percentage points.

Among the hypotheses proposed to explain the superior efficacy of neoadjuvant over adjuvant checkpoint inhibitor therapy is that stronger and more diverse T-cell responses are induced by neoadjuvant immunotherapy. This property is believed to be due to the presence of the entire tumor, and therefore the complete neoantigen repertoire, at the time the immunotherapy is initiated.<sup>21,22</sup> The addition of a CTLA-4 inhibitor to neoadjuvant PD-1 blockade improves the efficacy further, as shown in a phase 2 trial of neoadjuvant treatment, in pooled cross-trial comparisons, and in trials in stage IV melanoma.<sup>20,23–25</sup> Ipilimumab has been shown to broaden the tumor-specific T-cell rep-

**Table 3. Adverse Events.\***

Event	Neoadjuvant Group (N=212)	Adjuvant Group (N=208)
Any adverse event — no. (%)	204 (96.2)	194 (93.3)
Any grade $\geq 3$ adverse event — no. (%)	100 (47.2)	71 (34.1)
Serious adverse event — no. (%)	77 (36.3)	49 (23.6)
Treatment-related adverse event — no. (%)	196 (92.5)	178 (85.6)
Treatment-related grade $\geq 3$ adverse event — no. (%)	82 (38.7)	50 (24.0)
Surgery-related adverse event — no./total no. (%)	120/198 (60.6)	151/208 (72.6)
Surgery-related grade $\geq 3$ adverse event — no./total no. (%)	28/198 (14.1)	30/208 (14.4)
Adverse event related to systemic treatment — no./total no. (%)	181/212 (85.4)	123/170 (72.4)
Grade $\geq 3$ adverse event related to systemic treatment — no./total no. (%)	63/212 (29.7)	25/170 (14.7)
Discontinuation of treatment due to adverse event — no. (%)	19 (9.0)	30 (14.4)
Death due to treatment-related adverse event — no. (%)	0	1 (0.5)

\* Included are adverse events that were reported between randomization and 100 days after the last trial treatment. The safety population included all the patients who started trial treatment. Surgery-related adverse events were assessed in all the patients who underwent surgery. Adverse events related to systemic treatment were assessed in all the patients who received at least one dose of systemic treatment. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

ertoire and might therefore benefit patients who did not have a preexisting antitumor immune response before the start of checkpoint inhibitor therapy.<sup>26</sup> In line with these biologic observations, the combination of ipilimumab plus nivolumab in the NADINA trial seems to result in a higher 12-month event-free survival than neoadjuvant pembrolizumab (84% vs. 72%).<sup>7</sup> However, this advantage comes with higher toxicity, which emphasizes the need to identify subgroups of patients who may benefit from one or the other scheme; the efficacy of these treatments in specific subgroups of patients should be investigated in head-to-head comparison trials. Alternative neoadjuvant regimens with anti-PD-1 backbones (including the combination with anti-LAG-3, which has shown promising results in a phase 2 trial) could be considered for comparison with neoadjuvant ipilimumab plus nivolumab.<sup>27</sup>

The results of our trial confirm previous findings that indicate that the pathological response correlates with recurrence-free survival, although prolonged follow-up is needed to draw conclusions about its association with long-term outcomes.<sup>24</sup> In addition, this trial incorporated a response-driven adaptive strategy, resulting in a favorable 1-year recurrence-free survival among patients with a major pathological response (95.1%), even without adjuvant therapy. Recent updates from phase 2 trials indicate that this

strategy of omitting adjuvant therapy in patients with a major pathological response is safe and is associated with favorable long-term outcomes.<sup>28</sup> Because the majority of the patients in the neoadjuvant group in this trial had a major pathological response, allowing for de-escalation of adjuvant treatment, the effect on quality of life and health economics could be substantial. In the future, one could also envision de-escalation of surgery in patients who have a major pathological response, as in the PRADO trial.<sup>11,29</sup>

In the current trial, the recurrence-free survival was only 76.1% among patients with a pathological partial response, even though they received adjuvant treatment. Previous trials have shown either similar recurrence-free survival (73% in the PRADO trial) or better recurrence-free survival (100% in the OpACIN-neo trial) at 1 year without adjuvant treatment.<sup>11,15</sup> These data indicate that the subgroup of patients who had a pathological partial response might be too small and too heterogeneous in the individual trials, and therefore the role of adjuvant therapy in this subgroup remains poorly understood. Future (pooled) analyses are needed. With respect to patients who had a pathological nonresponse, the results of the current trial were consistent with those in the PRADO trial and the OpACIN-neo trial, which showed a reduction in the risk of recurrence with adjuvant therapy. However,

the estimated 1-year recurrence-free survival of 57.0% among the patients who had a pathological nonresponse indicates that new adjuvant therapies need to be explored in this subgroup.<sup>30</sup>

The success of such a response-driven adjuvant approach relies fundamentally on a robust response assessment by the local pathologist. The discrepancies between local and central pathological assessment were limited in our trial and were attributable to up-front education of the pathologists and adherence to the International Neoadjuvant Melanoma Consortium guidelines for pathological assessment.<sup>13</sup>

Despite the evident superiority of neoadjuvant treatment over adjuvant treatment, this first, pre-planned interim analysis reflects a relatively short follow-up. Follow-up is ongoing for the assessment of long-term event-free and distant metastasis-free

survival, health-related quality of life, and ultimately overall survival.

In this phase 3 trial, two cycles of neoadjuvant ipilimumab plus nivolumab was safe and resulted in longer event-free survival than adjuvant nivolumab among patients with resectable, macroscopic stage III melanoma.

Supported by Bristol Myers Squibb; a grant (MRFF2007157) in Australia from the National Health and Medical Research Council (NHMRC); an Investigator Grant (2022/GNT2018514) from the NHMRC (to Dr. Scolyer); an NHMRC Investigator Grant and funding from Nicholas and Helen Moore and Melanoma Institute Australia (to Dr. Menzies).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the patients and their families for participating in this trial; all our colleagues from the participating centers; Tara Mitchell, Alexander Eggermont, and Stefan Suci for their role on the data and safety and monitoring board; and Monica Osario, Jolanda Overweel, and Vikki Steel for administrative support.

#### APPENDIX

The authors' full names and academic degrees are as follows: Christian U. Blank, M.D., Ph.D., Minke W. Lucas, M.D., Richard A. Scolyer, M.D., Bart A. van de Wiel, M.D., Ph.D., Alexander M. Menzies, M.D., Ph.D., Marta Lopez-Yurda, Ph.D., Lotte L. Hoeijmakers, M.D., Robyn P.M. Saw, M.D., Judith M. Lijnsvelt, M.Sc., Nigel G. Maher, M.D., Saskia M. Pulleman, M.Sc., Maria Gonzalez, M.Sc., Alejandro Torres Acosta, M.Sc., Winan J. van Houdt, M.D., Ph.D., Serigne N. Lo, Ph.D., Anke M.J. Kuijpers, M.D., Ph.D., Andrew Spillane, M.D., W. Martin C. Klop, M.D., Ph.D., Thomas E. Pennington, M.D., Charlotte L. Zuur, M.D., Ph.D., Kerwin F. Shannon, M.D., Beatrijs A. Seinstra, M.D., Robert V. Rawson, M.D., John B.A.G. Haanen, M.D., Ph.D., Sydney Ch'ng, M.D., Ph.D., Kishan A.T. Naipal, M.D., Ph.D., Jonathan Stretch, M.D., Ph.D., Johannes V. van Thienen, M.D., Ph.D., Michael A. Rtshiladze, M.D., Sofie Wilgenhof, M.D., Ph.D., Rony Kapoor, M.D., Aafke Meerveld-Eggink, M.D., Ph.D., Lindsay G. Grijpink-Ongering, B.Sc., Alexander C.J. van Akkooi, M.D., Ph.D., Irene L.M. Reijers, M.D., David E. Gyoriki, M.D., Dirk J. Grünhagen, M.D., Ph.D., Frank M. Speetjens, M.D., Ph.D., Sonja B. Vlieg, M.D., Joanna Placzke, M.D., Lavinia Spain, M.D., Robert C. Stassen, M.D., Mona Amini-Adle, M.D., Céleste Lebbé, M.D., Ph.D., Mark B. Faries, M.D., Caroline Robert, M.D., Ph.D., Paolo A. Ascierto, M.D., Rozemarijn van Rijn, M.D., Ph.D., Franchette W.P.J. van den Berkmoortel, M.D., Ph.D., Djura Piersma, M.D., Ph.D., Andre van der Westhuizen, M.D., Gerard Vreugdenhil, M.D., Ph.D., Maureen J.B. Aarts, M.D., Ph.D., Marion A.M. Stevensen-den Boer, M.D., Ph.D., Victoria Atkinson, M.D., Muhammad Khattak, M.D., Ph.D., Miles C. Andrews, M.D., Ph.D., Alfons J.M. van den Eertwegh, M.D., Ph.D., Marye J. Boers-Sonderen, M.D., Ph.D., Geke A.P. Hospers, M.D., Ph.D., Matteo S. Carlino, M.D., Ph.D., Jan-Willem B. de Groot, M.D., Ph.D., Ellen Kapiteijn, M.D., Ph.D., Karijn P.M. Suijkerbuijk, M.D., Ph.D., Piotr Rutkowski, M.D., Ph.D., Shahneen Sandhu, M.D., Astrid A.M. van der Veldt, M.D., Ph.D., and Georgina V. Long, M.D., Ph.D.

The authors' affiliations are as follows: the Departments of Medical Oncology (C.U.B., M.W.L., L.L.H., J.M.L., S.M.P., J.B.A.G.H., K.A.T.N., J.V.T., S.W., A.M.-E., I.L.M.R.), Pathology (B.A.W.), Biometrics (M.L.-Y., A.T.A., L.G.G.-O.), Surgical Oncology (W.J.H., A.M.J.K., A.C.J.A.), and Isala Oncology Center, Isala Hospital, Zwolle (J.-W.B.G.) — all in the Netherlands; the Department of Hematology and Medical Oncology, University Clinic Regensburg, Regensburg, Germany (C.U.B.); Melanoma Institute Australia (R.A.S., A.M.M., R.P.M.S., N.G.M., M.G., S.N.L., A.S., T.E.P., K.F.S., R.V.R., S.C., J.S., M.A.R., A.C.J.A., M.S.C., G.V.L.), the Faculty of Medicine and Health (R.A.S., A.M.M., R.P.M.S., N.G.M., S.N.L., A.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A., G.V.L.), and Charles Perkins Centre (R.A.S., G.V.L.), University of Sydney, the Departments of Tissue Pathology and Diagnostic Oncology (R.A.S., R.V.R.) and Melanoma and Surgical Oncology (R.P.M.S., T.E.P., K.F.S., S.C., J.S., M.A.R., A.C.J.A.), Royal Prince Alfred Hospital, NSW Health Pathology (R.A.S., R.V.R.), the Departments of Medical Oncology (A.M.M., G.V.L.) and Breast and Melanoma Surgery (A.S.), Royal North Shore and Mater Hospitals, and the Department of Radiology, Mater Hospital (R.K.), Sydney, Royal Prince Alfred Hospital, Institute of Academic Surgery, Camperdown, NSW (A.C.J.A.), the Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC (D.E.G.), the Department of Medical Oncology,



Peter MacCallum Cancer Centre, East Melbourne, VIC (L.S., S.S.), Lake Macquarie Oncology, Lake Macquarie Private Hospital, the Department of Medical Oncology, Calvary Mater Hospital, and the Department of Medicine, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (A.W.), the Department of Medical Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), the Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA (M.K.), the Department of Medical Oncology, Alfred Health, Melbourne, and the Department of Medicine, School of Translational Medicine, Monash University, Melbourne, VIC (M.C.A.), and the Department of Medical Oncology, Westmead Hospital and Blacktown, Sydney (M.S.C.) — all in Australia; the Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (J.B.A.G.H.); the Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland (J.P., P.R.); the Department of Medical Oncology, Centre Léon Bérard, Lyon (M.A.-A.), Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-Oncology and Clinical Investigation Center, Cancer Institute AP-HP, Nord Paris Cité, INSERM Unité 976, Saint Louis Hospital, Paris (C.L.), and the Department of Medical Oncology, Gustave Roussy and Paris-Saclay University, Villejuif (C.R.) — all in France; the Department of Surgical Oncology, Angeles Clinic and Research Institute, Los Angeles (M.B.F.); and the Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy (P.A.A.).

## REFERENCES

1. Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol* 2020;21:1465-77.
2. Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. *NEJM Evid* 2022;1(11):EVIDoA2200214.
3. Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. *J Clin Oncol* 2018;36:3441-9.
4. Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. *Clin Cancer Res* 2023;29:3352-61.
5. Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. *Cancer Discov* 2016;6:1382-99.
6. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med* 2018;24:1655-61.
7. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med* 2023;388:813-23.
8. Patel S, Othus M, Prieto V, et al. LBA6 Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801). *Ann Oncol* 2022;33Suppl 7:S808-S869. abstract (<https://doi.org/10.1016/j.annonc.2022.08.039>).
9. Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol* 2019;20:948-60.
10. Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. *Nat Med* 2021;27:256-63.
11. Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. *Nat Med* 2022;28:1178-88.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-47.
13. Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol* 2018;29:1861-8.
14. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. *Biometrika* 1993;80:557-72.
15. Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. *Ann Oncol* 2023;34:420-30.
16. Weber J, Mandalá M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med* 2017;377:1824-35.
17. Eggermont AMM, Blank CU, Mandalá M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med* 2018;378:1789-801.
18. Derks SHAE, de Joode K, Mulder EEAP, et al. The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma. *ESMO Open* 2022;7:100600.
19. Bloemendal M, van Willigen WW, Bol KF, et al. Early recurrence in completely resected IIIB and IIIC melanoma warrants restaging prior to adjuvant therapy. *Ann Surg Oncol* 2019;26:3945-52.
20. Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. *J Clin Oncol* 2022;40:Suppl:9522. abstract ([https://doi.org/10.1200/JCO.2022.40.16\\_suppl.9522](https://doi.org/10.1200/JCO.2022.40.16_suppl.9522)).
21. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science* 2020;367(6477):eaax0182.
22. Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. *Nat Med* 2020;26:475-84.
23. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 2018;24:1649-54.
24. Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nat Med* 2021;27:301-9.
25. Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020;395:1558-68.
26. Kvistborg P, Philips D, Kelderman S, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. *Sci Transl Med* 2014;6(254):254ra128.
27. Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. *Nature* 2022;611:155-60.
28. Reijers ILM, Menzies AM, Versluis JM, et al. The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: three-year data of PRADO and OpACIN-neo. *J Clin Oncol* 2023;41:Suppl:101. abstract ([https://doi.org/10.1200/JCO.2023.41.16\\_suppl.101](https://doi.org/10.1200/JCO.2023.41.16_suppl.101)).
29. Lucas MW, Versluis JM, Rozeman EA, Blank CU. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. *Nat Rev Clin Oncol* 2023;20:408-22.
30. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. *Lancet* 2024;403:632-44.

Copyright © 2024 Massachusetts Medical Society.